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Outline
• Professional genomic and molecular medicine 
and consumer genetics
• The health field concept and the public health 
wheel
• The enterprise of Public Health Genomics 
(PHGEN)
• Genetic exceptionalism
• Ethical benchmarks
• Introduction and use of genome-based 
knowledge in the health services
• Stakeholder involvement
Newborn screening towards an 
earlier diagnosis and treatment
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Nascimentos continuam a descer: 
menos 5235 em Agosto do que  em 
mês homólogo de 2011 
Expresso 19.09.2012
year
N
e
w
b
o
r
n
 
s
c
r
e
e
n
e
d
The dawn of professional genomic and 
molecular medicine
Inherited thrombotic risk factors (Factor V, Factor 
II, PAI-1, MTHFR).
Demand (DGH): 
2006 – 310 samples
2007 – 389 samples
How to turn the knowledge of the genetic 
profile into action to prevent/control disease?
Genes on the Web — Direct-to-Consumer 
Marketing of Genetic Testing or Genetic 
horoscopes? 
A J Wolfberg. NEJM 2006;355:543-5. 
MyCellf Program:
A combined analysis of nineteen 
genes that may play an important 
role in how your body manages 
bone health, heart health, 
antioxidant and detoxification 
function, insulin sensitivity and 
“The science from the lab to your living  
room” 
inflammation. Perfect for those 
who want a complete snapshot of 
their overall health profile and 
recommendations for achieving 
optimal health without a specific 
disease focus.
Price: $269.00
A web-based service that helps you read and 
understand your DNA. After providing a saliva 
sample using an at-home kit, you can use our 
interactive tools to shed new light on your distant 
ancestors, your close family and most of all, 
yourself. 
Discover how your genes may affect your 
chances of developing various diseases and 
conditions, as well as traits as athletic ability.
www.genewatch.org
NicoTest:
“Sales pitch not science”
Environment
All the factors and 
systems outside the 
body that can affect 
Lifestyle
All the ‘decisions’ 
made by individuals 
that affect health, 
which they ‘control’: 
eating, exercise, 
smoking, alcohol, 
drugs, sexuality.
Health care system
All the resources and 
services devoted to 
health care: doctors, 
The health field concept (Lalonde 1974)
Human biology
All the internal 
systems and factors 
that affect physical 
and mental health: 
genetic, epigenetic 
and developmental.
health over which the 
person has little or no 
control: physical, 
chemical, biological, 
socio-economic. 
nurses, and allied 
professions; hospitals 
nursing homes, health 
centres, ambulances, 
etc. 
Time
Tarlov AR. Ann N Y Acad Sci. 1999;896:281-93.
Public Health Wheel: 
core functions, specific responsibilities and 
essential public health services
DGH, INSA
Public health genomics:
The responsible and effective translation of 
genome-based knowledge and technology for 
the benefit of population health.
Genome-based Research and Population Health, Bellagio 2005.
PHGEN at the crossroads of  science, 
health technology and society
Beyond the bench-to-bedside model of 
translational research
Bench 
(e.g., base pairs)
Bedside 
(promising tests and 
interventions)
Evidence-based Population
Knowledge 
synthesis 
T1
T2T0
Adapted from Khoury et al. Am J 
Public Health.  2012;102:34-7. 
recommendation or 
policy
Health care systems 
and prevention 
programs
health and 
brokering
T3T4
Genetic exceptionalism
Genetic information fundamentally differs from 
other kind of health information and – compared 
to non-genetic health information – should per 
se be protected in a special way. 
Is this true?
Ref: Hedgecoe A (1998) Medicine, Health Care and Philosophy 1: 235-43.
Genetic versus non-genetic information - I
• Concern for kin: genes can 
be passed on to children and 
as such can affect the family
• Concern for stigmatisation 
and discrimination: 
knowledge derived from 
analysing DNA provides 
• Tuberculosis or sexually 
transmitted diseases
• Leprosy and HIV
potential for stigmatising and 
discriminating persons or 
risk groups
• Concerns for easy 
accessibility of information 
and identification: DNA is a 
unique material to identify 
persons and is ubiquitous 
• IR thermal cameras at 
airports screen the body 
temperature of passengers; 
identical twins have different 
irises. 
Genetic versus non-genetic information - II
• Long-term storage and use 
for other purposes than 
originally consented for
• Concern for prophecy: 
knowing genes has a 
potential to tell with some 
• In the Dutch Bloodbank 14 
years after samples had 
been taken they were 
searched for antibodies for 
other purposes than 
originally intended
• HIV, Hepatitis B or high 
cholesterol can also foretell 
the risks and probabilities of 
probabilities something 
about a person’s future 
health
• The origination of health 
information: Health 
information in some cases 
stem from the analysis of a 
person’s genome 
a person’s future health 
• It can also come from 
analyses at the phenotype 
level
Right not 
to know
Right to 
know
Ethical benchmarks of PHGEN - I
Respecting autonomy / self-determination
Data 
protection
Data 
availability
Ethical benchmarks of PHGEN - II
Social justice
Individual self-
determination
Social 
justice “Equality of opportunity to be 
able to live an integral, self-
responsible life in order to take 
part in social communication” 
(P Dabrock 2003)
Empowerment of people to act as co-producers of their own health
Health and genetic literacy promotion as an ethical duty
R Veatch (2000) Doctor doesn’t know best: Why in the new century 
physicians must stop trying to benefit patients. J Med Phil 25:701-21
Introduction and use of genome-based 
knowledge in health services - I
• To what extent, when and in what order and 
manner genomic knowledge and technologies 
will give rise to effective and affordable clinical 
and public health interventions?
Prepare the ground
Antecipate all eventualities
• Genomic R&D findings are clinically valid and 
useful for human health
• Equity of access to clinical genetic services
• Adequate capacity and funding to respond to 
Introduction and use of genome-based 
knowledge in health services - II
scientific developments
Assessment tools are needed to systematically 
evaluate genome-based knowledge for public 
health purposes
• Public health approach:
– Health Needs Assessment (unmet needs; priorities; 
resource allocation)
Introduction and use of genome-based 
knowledge in health services – III
Assessment tools
– Health Technology Assessment (safety; efficacy; 
effectiveness; comparative effectiveness research; 
social and ethical implications)
– Health Impact Assessment (Health in all policies)
• Clinical genetics approach:
– ACCE model
HTA framework for genetic tests
ACCE model for evaluating genetic tests
Source: CDC, Public Health Genomics
Critical ACCE questions
In what clinical context is the genetic test going to be 
conducted? Confirmation of diagnosis, screening, predictive?
Has an internal quality control programme been defined and 
has it been monitored externally?
What is known about other genetic or environmental factors 
that can modify the effect of the genotype under study?
Is there any effective and acceptable intervention or other 
kind of benefit derived from performing the genetic test?
What human, material and economic resources are required 
for the provision of the necessary services?
What information is available on the impact of the test in 
terms of stigmatisation, discrimination and inequality in 
health? Orphan genotypes.
Sensitivity (r), specificity (s), predictive values (PPV, 
NPV), relative risk (RR) and efficiency (Eff) of a discrete 
test for the presence of a disease
r = a/(a+c)
s = d/(b+d)
PPV = a/(a+b)
NPV = d/(c+d)
RR = [a/(a+b)]/[c/(c+d)]
Eff = (a+d)/(a+b+c+d)
Status
Total
Diseased Non-diseased
Diagnostic
test
+ve
a (true +ve) b (false +ve)
Type I error
a+b
-ve
c (false –ve)
Type II error
d (true –ve) c+d
Total a+c b+d a+b+c+d
Ref: Tzouvelekis et al. Respiratory Research. 2005;6:78 
• DISEASE CHARACTERISTICS: 
– gene(s) involved, mutational spectrum; 
– analytical method validation; 
– incidence at birth (‘birth prevalence’) or population 
ESHG Clinical utility cards - I
prevalence; 
– diagnostic setting (differential diagnosis, predictive 
testing, risk assessment in relatives, prenatal).
• TEST CHARACTERISTICS: 
– analytical and clinical sensitivity and specificity; 
– clinical PPV and NPV.
• CLINICAL UTILITY: 
– (Differential) diagnosis:
• Can a diagnosis be made other than through a genetic test?
• Describe the burden of alternative diagnostic methods to the patient.
• How is the cost effectiveness of alternative diagnostic methods to be 
judged?
• Will disease management be influenced by the result of a genetic test?
– Predictive setting:
ESHG Clinical utility cards - II
• Will the result of a genetic test influence lifestyle and prevention?
• Which options in view of lifestyle and prevention does a person at risk have 
if no genetic test has been done?
– Genetic risk assessment in family members of a diseased person:
• Does the result of a genetic test resolve the genetic situation in that family?
• Can a genetic test in the index patient save genetic or other tests in family 
members?
• Does a positive genetic test result in the index patient enable a predictive 
test in a family member?
– Prenatal diagnosis:
• Does a positive genetic test result in the index patient enable a prenatal 
diagnosis?
ESHG Clinical utility cards - III
A molecular confirmation of the diagnosis will limit unnecessary 
further diagnostic investigations, which can be invasive (and 
expensive). 
Patients and family may find encouragement and support by 
becoming members of associations that welcome affected 
families. 
A molecular diagnosis enables carriers to make informed 
reproductive decisions.
Stakeholder involvement: 
Areas of public policy of concern to PHGEN
• Reproductive decision making (PND, PGD, population 
screening, ART, ...)
• Consent to testing and biobanking
• Privacy and confidenciality
• Discrimination in employment and insurance
• Test provision and laboratory performance
• Pharmacogenetics/genomics (personalised medicine)
• Gene and (stem) cell therapies
• Clinical R&D, including clinical trials
• IPR and patents
• R&D capacity
• Training of health professionals
• Genetic literacy of lay people
“Public health genomics: 
A population perspective 
on how genomics can 
improve health.”
Muin J. Khoury, MD, PhD 
Founding director of CDC′s 
National Office of Public Health 
Genomics 
